Literature DB >> 25327875

Irreversible electroporation: just another form of thermal therapy?

Martin J C van Gemert1, Peter G K Wagstaff, Daniel M de Bruin, Ton G van Leeuwen, Allard C van der Wal, Michal Heger, Cees W M van der Geld.   

Abstract

BACKGROUND: Irreversible electroporation (IRE) is (virtually) always called non-thermal despite many reports showing that significant Joule heating occurs. Our first aim is to validate with mathematical simulations that IRE as currently practiced has a non-negligible thermal response. Our second aim is to present a method that allows simple temperature estimation to aid IRE treatment planning.
METHODS: We derived an approximate analytical solution of the bio-heat equation for multiple 2-needle IRE pulses in an electrically conducting medium, with and without a blood vessel, and incorporated published observations that an electric pulse increases the medium's electric conductance.
RESULTS: IRE simulation in prostate-resembling tissue shows thermal lesions with 67-92°C temperatures, which match the positions of the coagulative necrotic lesions seen in an experimental study. Simulation of IRE around a blood vessel when blood flow removes the heated blood between pulses confirms clinical observations that the perivascular tissue is thermally injured without affecting vascular patency.
CONCLUSIONS: The demonstration that significant Joule heating surrounds current multiple-pulsed IRE practice may contribute to future in-depth discussions on this thermal issue. This is an important subject because it has long been under-exposed in literature. Its awareness pleads for preventing IRE from calling "non-thermal" in future publications, in order to provide IRE-users with the most accurate information possible. The prospect of thermal treatment planning as outlined in this paper likely aids to the important further successful dissemination of IRE in interventional medicine. Prostate 75:332-335, 2015.
© 2014 The Authors. The Prostate Published by Wiley Periodicals, Inc. © 2014 The Authors. The Prostate Published by Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25327875      PMCID: PMC4305196          DOI: 10.1002/pros.22913

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


Introduction

Irreversible electroporation (IRE) is (virtually) always called non-thermal 1,2, despite many reports showing that significant Joule heating occurs, that is, by mathematical modeling (e.g., 3), from measured temperatures that irreversibly injure tissues 4 and by histology showing coagulative necrosis in IRE-affected regions (e.g., 1,2,4–6). The classification “non-thermal” suggests that IRE at any setting induces cell death without the danger of Joule heating which make IRE procedures prone to serious thermal-related complications. Our first aim is therefore to validate with mathematical simulations that currently practiced IRE, in this paper comprising 1.5 or 2 kV over a needle-pair of 1 cm distance, 100 pulses of 0.1 ms duration per pulse and 1 Hz repetition frequency, has a non-negligible thermal response. Our second aim is to present a method that allows simple thermal treatment planning of IRE procedures. To achieve these goals, we will mathematically simulate the temperature response of multiple pulsed 2-needle IRE by (1) deriving an approximate analytical solution of the bio-heat equation for this IRE configuration in an electrically conducting medium, with and without a blood vessel, and (2) incorporating published observations that an electric pulse increases the medium's electric conductance. Finally, we compare the simulations with literature results.

Method

IRE Case 1: Tissue

We adopt the electric field distribution, E (kV/cm), as calculated by Davalos and Rubinsky 3 for 2 kV over a 1 cm needle distance. Their Figure 3B gives the resulting temperatures, ΔTmax, at the end of an electric pulse of Δt = 0.51 ms in tissue with an electric conductance of σ0 = 0.2 S/m from ΔTmax(r,Δt) = (σ0E(r)2/ρc) × Δt, with radial coordinate r, mass density ρ ≈ 103 (kg/m3) and heat capacity c ≈ 3.5 × 103 (J/kg/°C). The essence of our method is that we approximate ΔTmax by a Gaussian radial function and determine its 1/e-value at r = r0. With these two parameters the bio-heat Equation (1) below can be analytically solved, also for t ≫ Δt. The ΔTmax(r,Δt) curve of Figure 3B of 3 fits well as ΔTmax(r,0.51) ≈ ΔT0exp(−1.4 · r2), with ΔT0 = 21°C and r0 = 0.85 mm, from fitting ΔTmax at r = 0.5 and 0.828 mm. In our simulations we use 0.1 ms and 0.3 S/m (for prostate tissue 1), so ΔT0 = 6.28°C for 2 kV and 3.53°C for 1.5 kV. Further, σ0 increases during each IRE pulse 7 and the top of the peaks of Figure 4 of 7 fitted well to . At longer times, ΔT(r,t) follows from the solution of the bio-heat equation, which conserves the volumetric rates of heat produced by E and removed by thermal conduction. Ignoring heat loss by tissue perfusion 3, it is with thermal diffusivity α ≈ 0.13 mm2/s and 2nd order differential (Laplace) operator ∇2(m−2). Equation (1) has no simple general analytical solution. However, the Gaussian profile defined above may be thought to originate from radial cooling of an “instantaneous line source of heat” (8, Equation (1) of page 258) during time period τ = r02/4α ≈ 1.4 sec, where τ is the time constant for heat conduction. Then, a short IRE pulse at t = 0 has the simple thermal analytical solution to Equation (1) of Equation (1) is linear in ΔT so ΔT-responses to multiple pulses can be added as follows. We use that the 1st pulse, at t = 0, yields ΔT1(r,0) = ΔT0F1(r,0)σ1/σ0. Just after the 2nd pulse, say 1 sec later, the 1st pulse reduced to ΔT1(r,1) = ΔT0F1(r,1)σ1/σ0. The 2nd pulse gives ΔT2(r,1) ≡ΔT0F1(r,0)σ2/σ0, thus proportional to the response of the 1st pulse at t = 0. Two pulses, at t = 1 sec, thus cause ΔT2(r,1) = ΔT0[F1(r,0)σ2/σ0 + F1(r,1)σ1/σ0], that is, including the two responses to the first pulse at the two pulse events. Similarly, three pulses, at t = 2 sec, give ΔT(r,2) = ΔT0[F1(r,0)σ3/σ0 + F1(r,1)σ2/σ0 + F1(r,2)σ1/σ0]. Writing this as , using Equation (2) and including pulse rate f (Hz), approximately solves Equation (1) analytically following N consecutive pulses, at t = (N − 1)f−1 sec, as

IRE Case 2: Tissue With (Large) Blood Vessel

Two-needle IRE around a blood vessel can be simulated if blood flow removes the heated blood between pulses, keeping the intima at 37°C. An analytical solution to Equation (1) is available if radial cooling of the vessel wall is approximated by 1-D diffusion in the x-direction (intima at x = 0, Fig. 1), implying that the perivascular tissue becomes a 1-D semi-infinite medium. Using 8, Equation (1) of page 85, and that each pulse increases the whole perivascular tissue by ΔT0 °C, solves Equation (1) as ΔT(x,t) = ΔT0erf(x/). Thus, as Equation (3), an approximate solution of Equation (1) following N consecutive pulses, at t = (N − 1)f−1 sec, is
Figure 1

IRE around a blood vessel and 1-D heat conduction in the x-direction. The needles are assumed to be placed at 5 mm from the “center of the blood vessel.”

IRE around a blood vessel and 1-D heat conduction in the x-direction. The needles are assumed to be placed at 5 mm from the “center of the blood vessel.”

Results

Figure 2 shows simulations for f = 1 Hz.
Figure 2

Simulated temperatures, Equation (3), of 100 pulses of 2-needle IRE, for 1.5 kV over 1 cm distance, Δt = 0.1 ms, at 1 Hz, for prostate-resembling tissue 1 without (curves 1, 2, 3a, 3b, 4) and with a blood vessel, Equation (4), for 2 kV (red symbols). Curves 1, 2, 3a, 4 have been computed by fitting Figure 3B of 3 at radii 0.5 and 0.828 mm, and curve 3b by fitting two Gaussian functions at radii 0.5 and 0.828 mm (1st Gaussian) and 2 and 5 mm (2nd Gaussian), converted as before to 1.5 kV, Δt = 0.1 ms, and σ0 = 0.3 S/m, as: ΔTmax = 3.86 · exp [−(r/0.603)2] + 0.215 · exp [−(r/3.892)2]. Curves 1, 2, and 4 do not change much when using two Gaussians compared to one. The red triangles between curves 3a and 4 represent the curve “Vessel: 2 mm from intima.”

Simulated temperatures, Equation (3), of 100 pulses of 2-needle IRE, for 1.5 kV over 1 cm distance, Δt = 0.1 ms, at 1 Hz, for prostate-resembling tissue 1 without (curves 1, 2, 3a, 3b, 4) and with a blood vessel, Equation (4), for 2 kV (red symbols). Curves 1, 2, 3a, 4 have been computed by fitting Figure 3B of 3 at radii 0.5 and 0.828 mm, and curve 3b by fitting two Gaussian functions at radii 0.5 and 0.828 mm (1st Gaussian) and 2 and 5 mm (2nd Gaussian), converted as before to 1.5 kV, Δt = 0.1 ms, and σ0 = 0.3 S/m, as: ΔTmax = 3.86 · exp [−(r/0.603)2] + 0.215 · exp [−(r/3.892)2]. Curves 1, 2, and 4 do not change much when using two Gaussians compared to one. The red triangles between curves 3a and 4 represent the curve “Vessel: 2 mm from intima.”

IRE Case 1

For prostate tissue, 1.5 kV over 1 cm, Δt = 0.1 ms, N = 100 1, a temperature of 92°C occurs at the needle-tissue boundary (curve 1), which falls to 80°C at r = 1 mm (curve 2) and 56°C at r = 3 mm (curve 3a). However, at r = 3 mm, the Gaussian fit used gives ΔTmax ≈ 0 rather than ≈0.55°C which results in an 11°C underestimated temperature at N = 100, thus a better value than 56°C is 67°C (curve 3b), based on including two Gaussian functions for ΔTmax (defined in the caption of Fig. 2). Coordinate r = 3 mm matches the position of the lesion margin shown in Figure 4 of 1, implying that these pathology-assessed coagulative necrotic lesions are thermal injuries that correspond with our computed temperatures of 67–92°C.

IRE Case 2

For a (large) blood vessel at r = 5 mm, 2 kV over the needles, ΔT0 ≈ 0.15°C (from ΔT0 ≈ 0.5°C in Figure 3B of 3), we simulate a temperature of 41°C close to the intima but 53°C at 2 mm from the intima (thus at r = 3 mm). We neglected the extra ≈ 0.5°C shown in Figure 3B of 3 at r = 3 mm which would have added another ≈10°C. In our opinion, this explains for the first time why IRE of blood vessels is effective and safe 6. It suggests a clinical role for matching the measured blood flow with the IRE pulse frequency.

Discussion

The message of this paper is that although one single IRE pulse may raise the temperature a few degrees only, 100 consecutive pulses can produce temperatures that easily injure tissues irreversibly. From that standpoint, IRE is not different from other Joule heating-based therapies. Particularly, tissues of large electric conductance warrant caution during IRE, for example, urine (1.9 S/m 9) within the renal collecting system and bile ducts when filled with bile (1.27 S/m 9). To the best of our knowledge, we are the first to analytically solve, albeit approximately, the temperature response to multiple-pulsed IRE by fitting the electric field distribution to a Gaussian function. The linearity of Equation (1) in ΔT obviously allows this approach to be extended to the use of more than just one Gaussian (see curve 3b of Fig. 2 for two Gaussians). Thermal treatment planning becomes simple now, based on Equation (3), and can conceptually be extended to multiple-needle IRE geometries with programmed activation of the various needle-pairs. Treatment planning before—as well as temperature measurements during—IRE oncologic procedures are particularly important because insufficient thermal effects at the boundaries of treated lesions are notorious for causing tumor recurrence. Compared to the numerical analysis in 10, we achieved very similar results, for example, the first two T-peaks of their Figure 5, that is, T ≈ 33.8 and ≈34°C in response to 40 pulses of 0.5 kV over 0.5 cm and 0.05 ms, in sets of 20 separated by 3.5 sec, versus our estimates of ≈33.7 and 34.2°C. Further, the literature gives thermal evaluations of 2-plate and multiple-needle IRE. The former has negligible heat conduction during multiple pulses, the latter likely gives slightly higher temperatures compared to 2-needle IRE. As an example, Faroja et al. 4 measured temperatures as high as 84°C of 2-plate IRE (their Table 1) in in vivo porcine liver, using 2.5 kV over a 1 cm plate distance and 360 pulses of 0.1 ms at 1 Hz. For 40 and 90 pulses at 2.5 kV they found ΔT ≈ 11 and 18°C. Using ΔT =  and σ0 ≈ 0.09 S/m for liver 9, gave ΔT ≈ 15 and 39°C. Also, non-thermal IRE effects have been documented, for example, by Gehl et al. (Fig. 3 of 11), using 2-plate IRE around the tibia of mice, eight pulses at 0.2–1.4 kV/cm and Δt of 10–2,000 µs. These authors described perfusion delays of 200–1,800 sec, which they attributed to sympathetic nerve-mediated reflexory vasoconstriction of afferent arterioles, characterized as a Raynaud-like phenomenon and comparable to ST depression observed in the ECG of patients following atrial defibrillation. The reported perfusion delays correspond to simulated temperature increases of 2–33°C. The thermal nature of IRE may actually have several important therapeutic consequences in terms of cancer treatment. As described in 12, exposure of cancer cells to IRE induces necrotic 1,2,4–6 and possibly apoptotic and/or autophagic cell death. Any of these forms of cell death activates the immune system through sterile inflammation 13, leading to debridement of necrotic tissue followed by tissue remodeling. It is also likely that the adaptive immune system elicits an anti-tumor immune response against residual, viable cancer cells in the treated volume as well as distal, non-treated cancer cells 14.

Conclusion

The demonstration that significant thermal effects at current IRE settings cannot be ignored hopefully contributes to future in-depth discussions on thermal issues that surround IRE. This is an important subject because it has long been under-exposed in literature. Such a discussion adds to safer and more precisely planned IRE procedures. The thermal nature of current IRE practice pleads for preventing IRE from calling “non-thermal” in future publications, in order to provide IRE-users with the most accurate information possible. The prospect of treatment planning as outlined above may aid to the important further successful dissemination of IRE in interventional medicine.
  12 in total

1.  Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery.

Authors:  Julie Gehl; Torben Skovsgaard; Lluis M Mir
Journal:  Biochim Biophys Acta       Date:  2002-01-15

2.  Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma.

Authors:  Patricia Soo-Ping Thong; Kong-Wee Ong; Nicholas Seng-Geok Goh; Kiang-Wei Kho; Vanaja Manivasager; Ramaswamy Bhuvaneswari; Malini Olivo; Khee-Chee Soo
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

Review 3.  Endovascular laser–tissue interactions and biological responses in relation to endovenous laser therapy.

Authors:  Michal Heger; Rowan F van Golen; Mans Broekgaarden; Renate R van den Bos; H A Martino Neumann; Thomas M van Gulik; Martin J C van Gemert
Journal:  Lasers Med Sci       Date:  2014-03       Impact factor: 3.161

4.  Electrical conductivity of tissue at frequencies below 1 MHz.

Authors:  C Gabriel; A Peyman; E H Grant
Journal:  Phys Med Biol       Date:  2009-07-27       Impact factor: 3.609

5.  In vivo electrical conductivity measurements during and after tumor electroporation: conductivity changes reflect the treatment outcome.

Authors:  Antoni Ivorra; Bassim Al-Sakere; Boris Rubinsky; Lluis M Mir
Journal:  Phys Med Biol       Date:  2009-09-17       Impact factor: 3.609

6.  Irreversible electroporation ablation: is all the damage nonthermal?

Authors:  Mohammad Faroja; Muneeb Ahmed; Liat Appelbaum; Eliel Ben-David; Marwan Moussa; Jacob Sosna; Isaac Nissenbaum; S Nahum Goldberg
Journal:  Radiology       Date:  2012-11-20       Impact factor: 11.105

Review 7.  Nonthermal irreversible electroporation: fundamentals, applications, and challenges.

Authors:  Alexander Golberg; Martin L Yarmush
Journal:  IEEE Trans Biomed Eng       Date:  2013-01-09       Impact factor: 4.538

8.  Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation.

Authors:  Edward W Lee; Christine Chen; Veronica E Prieto; Sarah M Dry; Christopher T Loh; Stephen T Kee
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

Review 9.  Danger signals activating the immune response after trauma.

Authors:  Stefanie Hirsiger; Hans-Peter Simmen; Clément M L Werner; Guido A Wanner; Daniel Rittirsch
Journal:  Mediators Inflamm       Date:  2012-06-19       Impact factor: 4.711

10.  A parametric study delineating irreversible electroporation from thermal damage based on a minimally invasive intracranial procedure.

Authors:  Paulo A Garcia; John H Rossmeisl; Robert E Neal; Thomas L Ellis; Rafael V Davalos
Journal:  Biomed Eng Online       Date:  2011-04-30       Impact factor: 2.819

View more
  13 in total

Review 1.  Heating technology for malignant tumors: a review.

Authors:  H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

Review 2.  [Irreversible electroporation. Current value for focal treatment of prostate cancer].

Authors:  J J Wendler; R Ganzer; B Hadaschik; A Blana; T Henkel; K U Köhrmann; S Machtens; A Roosen; G Salomon; L Sentker; U Witzsch; H P Schlemmer; D Baumunk; J Köllermann; M Schostak; U B Liehr
Journal:  Urologe A       Date:  2015-06       Impact factor: 0.639

Review 3.  [Focal therapy of prostate cancer in Germany].

Authors:  M Apfelbeck; A Herlemann; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

4.  The efficacy and safety of irreversible electroporation for the ablation of renal masses: a prospective, human, in-vivo study protocol.

Authors:  Peter G K Wagstaff; Daniel M de Bruin; Patricia J Zondervan; C Dilara Savci Heijink; Marc R W Engelbrecht; Otto M van Delden; Ton G van Leeuwen; Hessel Wijkstra; Jean J M C H de la Rosette; M Pilar Laguna Pes
Journal:  BMC Cancer       Date:  2015-03-22       Impact factor: 4.430

5.  Comment to: Månsson C, Nilsson A, Karlson B-M. Severe complications with irreversible electroporation of the pancreas in the presence of a metallic stent: a warning of a procedure that never should be performed. Acta Radiologica Short Reports 2014;3(11):1-3.

Authors:  Hester J Scheffer; Jantien A Vogel; Willemien van den Bos; Martijn R Meijerink; Marc Gh Besselink; Rudolf M Verdaasdonk; John Klaessens; Cees Wm van der Geld; Martin Jc van Gemert
Journal:  Acta Radiol Open       Date:  2015-07-07

6.  Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.

Authors:  Matthijs J V Scheltema; Willemien van den Bos; Daniel M de Bruin; Hessel Wijkstra; M Pilar Laguna; Theo M de Reijke; Jean J M C H de la Rosette
Journal:  BMC Cancer       Date:  2016-05-05       Impact factor: 4.430

7.  Percutaneous Irreversible Electroporation of Unresectable Hilar Cholangiocarcinoma (Klatskin Tumor): A Case Report.

Authors:  Marleen C A M Melenhorst; Hester J Scheffer; Laurien G P H Vroomen; Geert Kazemier; M Petrousjka van den Tol; Martijn R Meijerink
Journal:  Cardiovasc Intervent Radiol       Date:  2015-05-21       Impact factor: 2.740

8.  Irreversible Electroporation Ablation of an Unresectable Fibrous Sarcoma With 2 Electrodes: A Case Report.

Authors:  Zilin Qin; Jianying Zeng; Guifeng Liu; Xinan Long; Gang Fang; Zhonghai Li; Kecheng Xu; Lizhi Niu
Journal:  Technol Cancer Res Treat       Date:  2017-05-31

9.  The Influence of a Metal Stent on the Distribution of Thermal Energy during Irreversible Electroporation.

Authors:  Hester J Scheffer; Jantien A Vogel; Willemien van den Bos; Robert E Neal; Krijn P van Lienden; Marc G H Besselink; Martin J C van Gemert; Cees W M van der Geld; Martijn R Meijerink; John H Klaessens; Rudolf M Verdaasdonk
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

Review 10.  Irreversible electroporation: state of the art.

Authors:  Peter Gk Wagstaff; Mara Buijs; Willemien van den Bos; Daniel M de Bruin; Patricia J Zondervan; Jean Jmch de la Rosette; M Pilar Laguna Pes
Journal:  Onco Targets Ther       Date:  2016-04-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.